Company Description
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.
The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians’ offices, reference laboratories, and other critical care settings.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
| Country | United States |
| Founded | 1969 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 63,000 |
| CEO | Rainer Blair |
Contact Details
Address: 2200 Pennsylvania Avenue N.W., Suite 800W Washington, District of Columbia 20037-1701 United States | |
| Phone | 202 828 0850 |
| Website | danaher.com |
Stock Details
| Ticker Symbol | DHR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000313616 |
| CUSIP Number | 235851102 |
| ISIN Number | US2358511028 |
| Employer ID | 59-1995548 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Rainer M. Blair | President, Chief Executive Officer and Director |
| Steven M. Rales | Co-Founder and Chairman |
| Mitchell P. Rales | Co-Founder and Director |
| Matthew R. McGrew | Chief Financial Officer and Executive Vice President |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Senior Vice President and Chief Science Officer |
| Georgeann F. Couchara | Senior Vice President of Human Resources |
| Christopher M. Bouda | Vice President and Chief Accounting Officer |
| John Bedford | Vice President of Investor Relations |
| Brian W. Ellis J.D. | Senior Vice President, General Counsel and Chief Compliance Officer |
| Daniel A. Raskas J.D. | Senior Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | ARS | Filing |
| Mar 26, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2025 | 144 | Filing |
| Feb 21, 2025 | 144 | Filing |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | 144 | Filing |
| Feb 7, 2025 | 144 | Filing |
| Jan 30, 2025 | 144 | Filing |